An in vitro method for prognosticating clinical progression and/or predicting the risk of recurrence of a papillary lesion of the breast, selected from method and method, wherein A) method comprises - detecting the presence of proCOL11A1 protein in a sample from a subject diagnosed with a papillary lesion of the breast; wherein - detection of the presence of proCOL11A1 protein in said sample from a subject diagnosed with a papillary lesion of the breast is indicative that the risk of recurrence is high, or - non-detection of the presence of proCOL11A1 protein in said sample from a subject diagnosed with a papillary lesion of the breast is indicative that the risk of recurrence is low, and B) method comprises - comparing the proCOL11A1 protein expression level in said sample with said proCOL11A1 protein expression level in a control sample; wherein - a proCOL11A1 protein expression level in said sample from a subject diagnosed with a papillary lesion of the breast greater than said proCOL11A1 protein expression level in a control sample is indicative that the risk of recurrence is high, or - a proCOL11A1 protein expression level in said sample from a subject diagnosed with a papillary lesion of the breast equal to or less than said proCOL11A1 protein expression level in a control sample is indicative that the risk of recurrence is low. A) method comprises - detecting the presence of proCOL11A1 protein in a sample from a subject diagnosed with a papillary lesion of the breast; wherein - detection of the presence of proCOL11A1 protein in said sample from a subject diagnosed with a papillary lesion of the breast is indicative that the risk of recurrence is high, or - non-detection of the presence of proCOL11A1 protein in said sample from a subject diagnosed with a papillary lesion of the breast is indicative that the risk of recurrence is low, and - detecting the presence of proCOL11A1 protein in a sample from a subject diagnosed with a papillary lesion of the breast; - detection of the presence of proCOL11A1 protein in said sample from a subject diagnosed with a papillary lesion of the breast is indicative that the risk of recurrence is high, or - non-detection of the presence of proCOL11A1 protein in said sample from a subject diagnosed with a papillary lesion of the breast is indicative that the risk of recurrence is low, and B) method comprises - comparing the proCOL11A1 protein expression level in said sample with said proCOL11A1 protein expression level in a control sample; wherein - a proCOL11A1 protein expression level in said sample from a subject diagnosed with a papillary lesion of the breast greater than said proCOL11A1 protein expression level in a control sample is indicative that the risk of recurrence is high, or - a proCOL11A1 protein expression level in said sample from a subject diagnosed with a papillary lesion of the breast equal to or less than said proCOL11A1 protein expression level in a control sample is indicative that the risk of recurrence is low. - comparing the proCOL11A1 protein expression level in said sample with said proCOL11A1 protein expression level in a control sample; - a proCOL11A1 protein expression level in said sample from a subject diagnosed with a papillary lesion of the breast greater than said proCOL11A1 protein expression level in a control sample is indicative that the risk of recurrence is high, or - a proCOL11A1 protein expression level in said sample from a subject diagnosed with a papillary lesion of the breast equal to or less than said proCOL11A1 protein expression level in a control sample is indicative that the risk of recurrence is low.